MassChallenge

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy and improve patient outcomes for fertility clinics and reproductive specialists.

Pharmesol is a technology company that specializes in automating post-prescription care through its clinical services platform. The platform uses artificial intelligence to facilitate communication between patients, healthcare providers, and pharmacies, ensuring efficient follow-up care for medications. It streamlines calls and messages while maintaining recorded documentation, providing round-the-clock personalized support for both patients and doctors.

Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

CranioSense is bringing intracranial hypertension into the light by simplifying the diagnostic process across the clinical spectrum.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Electronrx specializes in personalized digital medicine, focusing on the development of innovative solutions for chronic disease management and hospital patient care. The company leverages a multidisciplinary team, comprising experts in biomedical engineering, data science, machine learning, computer engineering, mathematics, physics, neuroscience, and drug discovery. Electronrx's predictive healthcare and diagnostics platform is designed to monitor physiological conditions and facilitate personalized therapeutic interventions. Its products enable remote monitoring of cardiovascular health by clinical professionals, delivering short waveforms of current and voltage to provide relief. This technology empowers patients to self-monitor their health and effectively manage conditions such as period pain during treatment.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. This technology enables Narval to create novel first-in-class immunotherapeutics for diseases previously challenging to treat using monoclonal antibodies. Their focus includes respiratory, eye, and autoimmune diseases, with delivery methods such as inhaled antibodies, eye drops, and transdermal patches. Narval leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Flagler Health is a developer of clinical decision support software aimed at enhancing healthcare delivery. The company's platform leverages patient data and clinical guidelines to assist physicians in identifying beneficial treatment strategies that may have been overlooked. By integrating artificial intelligence technologies, Flagler Health transforms clinics into more efficient health systems, enabling healthcare providers to offer comprehensive care and improve patient outcomes. Its focus on data-driven insights positions Flagler Health as a valuable partner in the healthcare sector, facilitating informed decision-making for clinicians.

Stellate Therapeutics is a private biotechnology company that specializes in the development of small molecules derived from human gut bacteria, aimed at creating personalized therapies for neurological diseases. The company focuses on researching the gut-brain axis and its implications for age-related neurological conditions. Stellate has established a robust portfolio of drug candidates, including AMA-101, which is positioned as a potential first-in-class therapy for Parkinson's disease. Through its innovative microbiome-derived medicine platform, Stellate Therapeutics engages in various stages of drug development, including discovery, screening, production, and diagnostic development, with the goal of providing effective treatments for patients suffering from neurological disorders.

Trove Health is a company that offers a clinical trial recruitment platform designed to facilitate access to patient data for patients, healthcare providers, and life sciences organizations. The platform creates a diverse and consented database of prospective trial participants, enabling researchers to efficiently identify and recruit patients who meet specific enrollment criteria across various geographies and therapeutic areas. By doing so, Trove Health supports the advancement of medical research while empowering patients to manage their own health data, including the potential to monetize it and receive personalized treatment options.

Symphony Biosciences is a biotechnology company dedicated to developing innovative cancer treatments that target solid tumors, with a primary focus on triple-negative breast cancer. Recognizing the limitations of existing therapies, which often involve toxic chemotherapies with poor survival rates, Symphony Biosciences aims to orchestrate the immune response to improve outcomes for patients. The company's research emphasizes the use of biomaterials to enhance cancer treatment options, providing healthcare professionals with effective tools to combat challenging cancer types. Through its focused efforts, Symphony Biosciences strives to advance the field of oncology and improve the quality of care for patients facing solid tumors.

Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Eupnoos is a health-tech company focused on enhancing lung health and disease detection through innovative smartphone technology. Its platform provides clinical-grade, device-agnostic automated lung function testing and data interpretation, accessible via an API for various monitoring devices. Utilizing the smartphone's microphone and camera, Eupnoos enables users to screen, measure, and assess their lung function and symptoms effectively. The company's services support both clinical and consumer-grade applications, facilitating telehealth and remote patient monitoring. By offering tools that help individuals understand their lung health, Eupnoos empowers users to access wellness monitoring and improve clinical decision-making with professional guidance.

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Selmod, located in Basel, Switzerland, specializes in the development of innovative small molecule therapies aimed at treating life-threatening, multi-drug resistant infections. The company is committed to discovering and advancing first-in-class drug candidates that provide second-line and last-resort treatment options for patients in hospital settings, particularly where conventional therapies have failed due to resistance. Selmod's approach includes the development of antibiotics with dual modes of action to effectively counteract existing resistance mechanisms. Its leading candidates, SLM500, SLM100, and SLM300, have demonstrated success in preclinical animal studies and are positioned within a promising market projected to exceed $9 billion. The company aims to capture a substantial market share shortly after entry, supported by a leadership team with extensive experience in clinical development for major pharmaceutical firms. Funding will be utilized to advance SLM500 through IND-enabling studies and to optimize additional lead candidates for further development.

Ronawk is a biotechnology company specializing in the development of T-Block technology that produces patient-specific biologics for the treatment of various diseases, including cancer, organ injuries, and burns. The company's proprietary method allows for the growth of primary stem cells in a three-dimensional environment, preserving the essential characteristics of these cells outside the human body. This innovative approach enables the rapid expansion of stem cells, facilitating their use in early-stage diagnostics and the repair of damaged tissues. Ronawk's technology not only enhances the efficiency of growing human cells but also supports tissue generation and disease modeling, making significant contributions to the fields of regenerative medicine and reconstructive surgery.

Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

Condor Software is a provider of clinical finance software that enhances financial decision-making in the clinical development sector. The company specializes in integrating real-time clinical trial data with third-party vendor collaboration, facilitating more accurate accounting processes. By leveraging financial intelligence and automation alongside deep industry expertise, Condor Software enables pharmaceutical and biotech companies to optimize their financial resources and streamline complex workflows. Its software allows for efficient management of clinical accruals, forecasts, and financial plans, which helps organizations reduce time spent on cash flow management. Ultimately, Condor Software aims to accelerate the development of life-changing medical breakthroughs by empowering companies to make informed business decisions that drive innovation and impact.

Nightingale Caring Solutions is a company focused on enhancing nursing care delivery through advanced technology and analytics. By utilizing machine learning and big data, it provides hospital administrators with insights into the relationships between individual nurses and patient outcomes. This enables healthcare facilities to optimize various aspects of nursing operations, including staffing, scheduling, and nurse-patient assignments. The company's solutions aim to improve the efficiency and safety of healthcare systems, ultimately leading to better patient care and outcomes. Nightingale Caring Solutions empowers nurse stakeholders with visualizations and analytics that facilitate informed decision-making in hiring, training, and workforce management.

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

Fora Health helps patients and clinicians track health and take part in shared decision-making. The company's platform links a patient-facing smartphone app with a clinical team web interface, powering remote patient monitoring and shared decision making. Fora Health is scaled to the needs of clinical teams, configuring data collected from validated ePROs and cognitive assessments, to goal tracking, medication adherence, and side effect tracking.

BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device that facilitates blood type analysis and the detection of various infectious diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. The company's portable platform operates independently of electricity and does not require additional laboratory infrastructure, making it accessible for use in diverse settings. Criam's device allows for rapid and accurate blood testing, which enhances clinical decision-making by providing timely health information. The technology is designed to be scalable, with one reader capable of performing multiple tests using specialized cartridges and computer vision algorithms. This innovation aims to improve the efficiency and reliability of blood testing services, ultimately enhancing patient care.

Paragit Solutions specializes in developing innovative systems for remote patient monitoring and data-driven clinical management of movement disorders, particularly Parkinson's disease. Central to their offerings is the Paragit Sleeve, which employs a patented sEMG (electromyography) technology to gather precise data on muscle activation, movement, and grip force during patients' daily activities. Paragit provides two main software suites for data interpretation: the PD Monitor, tailored for caregivers, which visualizes key motor symptoms like rigidity and tremors to enhance treatment optimization and facilitate telemedicine; and the MD Lab, designed for decentralized clinical trials across various movement disorders. MD Lab enables researchers to analyze over 20 metrics related to disease severity, track trends, and compare groups consistently, with a robust API that supports extensive data access for further analysis. Through these technologies, Paragit aims to improve the management and understanding of movement disorders, enhancing patient care and clinical research.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Leucine Rich Bio is a pioneering genomics-based company in India, focused exclusively on the human microbiome, often referred to as the "Second Genome." By leveraging advanced genomic techniques, the company aims to address crucial uncertainties in precision medicine related to the microbiome's impact on health and wellness. Leucine Rich Bio offers a unique platform that provides customized nutritional recommendations and personalized supplements tailored to an individual's intestinal microflora. Its applications span various medical fields, including gastroenterology, endocrinology, oncology, mental health, and reproductive health, enabling clients to achieve clinical resolutions and improve overall well-being. The company is dedicated to advancing understanding and utilization of microbiome research for better health outcomes.

BestHealth4U is a company focused on researching and developing advanced medical adhesive technologies aimed at enhancing patient health and safety. The company offers innovative, eco-friendly adhesive solutions that prevent skin injuries, accelerate healing, and improve overall patient well-being. By transforming the attachment methods of bandages, dressings, and medical devices, BestHealth4U addresses common issues such as skin damage, pain, irritation, and infection caused by traditional medical adhesives. Its commitment to creating safe and effective products positions the company as a leader in the medical device industry, particularly in the realm of class 1 medical devices.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative MIVO® (Multi In Vitro Organ) technology, which represents the next generation of organ-on-a-chip systems. This microphysiological platform allows scientists to replicate human biology in the laboratory more accurately, addressing the limitations of traditional in vitro assays and animal models. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. The company aims to improve laboratory testing effectiveness while reducing reliance on animal testing, facilitating the cultivation of three-dimensional tissues that closely resemble human tissues for more clinically relevant in vitro experiments.

Matricelf is a biotechnology company focused on advancing tissue engineering and regenerative medicine. Founded in 2019 by Professor Tal Dvir from Tel Aviv University, the company specializes in the 3D printing of tissues and organs, utilizing a proprietary decellularization process that extracts stromal cells and extracellular matrix from small biopsy samples. This process generates a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells to create functional tissues through a patent-pending methodology. Matricelf is particularly dedicated to developing spinal cord implants for patients with traumatic injuries, aiming to restore neuronal activity and enhance motor functions, thereby improving patients' quality of life and facilitating their reintegration into the community.

UpLift Health Inc., based in Atlanta, Georgia, specializes in developing a digital application aimed at treating depression through cognitive behavioral therapy (CBT). Founded in 2018, the company offers a structured program that consists of twelve weekly sessions, each lasting approximately 40 minutes, designed to teach users effective coping skills. The application incorporates chatbot-guided interactions, allowing users to engage with mental exercises and receive feedback. Additionally, it provides daily tools for users to apply learned skills in their everyday lives. Preliminary research indicates that UpLift's program can significantly reduce symptoms of depression, with a reported reduction of 52% in pilot studies. The company is focused on its mission to assist one million individuals in overcoming depression.

Julota is a community interoperability platform designed to enhance public health and safety by optimizing the use of local resources. It facilitates collaboration among emergency responders, clinicians, and caseworkers through an opt-in network that can be accessed anywhere. The platform integrates existing community-based organizations, whether public, private, or charitable, to address pressing issues such as mental health, opioid addiction, and emergency interventions. By enabling various entities to locate patients, identify problems, conduct assessments, manage privacy concerns, and develop comprehensive community care teams, Julota aims to multiply the impact of limited resources and foster a more interconnected approach to social and health challenges.

KnowRX Health is a developer of a cloud-based digital healthcare platform designed to enhance therapeutic care through personalized patient engagement. The platform utilizes machine learning technology, Maestro ML™, to create tailored care circles that facilitate clinical trial participation, improve medication adherence, and conduct focused surveys. It engages patients in daily wellness activities, encompassing nutritional, psychological, and physical health. The KnowRX platform serves as a resource for both patients and healthcare providers, offering critical drug information and updated clinical trial reports to inform therapy decisions. Additionally, it provides access to counseling, genomics data for treatment compatibility, nutritional guidance, and educational resources, all aimed at optimizing treatment outcomes and empowering patients in their self-care journey.

NUBIX stores and remotely interprets specialty studies connecting specialist with clinics, hospitals, laboratories and public and private cabinets, insurers and patients. We support the diagnosis by managing, storing and interpreting studies of specialty in 3 simple steps: storage of studies, access to studies from anywhere and interpretation of the study at any time. We improve the communication systems available between clinics and hospitals with medical specialists. Our focus is on 3 areas: insurers that seek to reduce their costs based on the reduction of mounted claims, clinics and public and private hospitals that do not have a radiologist or other specialist in their staff, to the public health sector as a third party authorized for distance interpretation and patients who are seeking a second medical opinion about their medical procedures. During its first year of operations (2018) NUBIX serves more than 39,000 patients including more than 35,000 patients for the early detection of breast cancer. Times of up to 25 hours for patient care are achieved through NUBIX compared to other options that take more than a month to perform the interpretation, this is very important since with most types of cancer Breast division takes one to two months, that is, the lesion doubles in size from a treatable finding to a high-risk one.

Sano Chemicals is an early-stage biotechnology company dedicated to developing innovative anti-infectives for both clinical and agricultural applications. The company derives its name from the Latin word for health, reflecting its mission to create products that enhance health and promote a sustainable environment. Sano Chemicals specializes in antifungal treatments, focusing on the unique compound occidiofungin, which was discovered by researchers at Mississippi State University and Texas A&M University. This compound is being explored for various applications, including treatments for fungal infections in humans, such as nail and skin infections, as well as systemic issues. Additionally, Sano Chemicals is committed to developing antifungal bio-control methods for crops, aiming to protect plants from fungal diseases and contribute to sustainable food production. Through its innovative research, Sano Chemicals seeks to transform the antifungal industry and improve the quality of life for patients and agricultural practices.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Knot is a developer of a modern case log application designed to support medical professionals and enhance patient care. The application facilitates the logging of surgical cases through a mobile platform, allowing clinicians to efficiently document their medical activities. It promotes learning and simplifies the reporting of surgical residency requirements for residents, making it an essential tool for both doctors and patients in the healthcare ecosystem. By streamlining case documentation, Knot contributes to improving the overall efficiency of medical practices and residency training.

Byteflies is a Belgian-American wearable health company dedicated to transforming healthcare through innovative technology. With its headquarters in Antwerp, Belgium, near key life sciences and clinical research centers, and a secondary office in the San Francisco Bay Area, the company is positioned at the intersection of healthcare and digital innovation. Byteflies develops advanced wearable health applications, including a sensor dot that captures biopotential signals, muscle activity, eye movement, and other activity-related data using an integrated inertial measurement unit. This technology empowers pharmaceutical companies, researchers, and tech firms to enhance healthcare delivery and improve patient outcomes. The team comprises experts in medicine, engineering, and data science, all committed to advancing health monitoring and management.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Savvy Cooperative is a company that operates a platform focused on sharing health experiences within the healthcare industry. The platform enables patients to directly share their health journeys with innovators in the field, advocating for fair compensation for their contributions. By doing so, Savvy empowers patients to co-create new healthcare solutions, providing them with a sense of purpose and an opportunity to earn money. This approach helps healthcare industries gain valuable patient insights for clinical research, user experience design, and market analysis through various methods such as surveys, interviews, and focus groups.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Health Note is an AI chatbot platform based in San Francisco, California, founded in 2018. The company specializes in health data management, focusing on enhancing patient encounters by streamlining the collection of patient information. By sending an SMS link to patients, Health Note connects them to its AI-driven chatbot, which gathers pre-visit data and formats it into physician notes. This process simplifies documentation for healthcare providers and integrates seamlessly with existing electronic medical record systems, ensuring a frictionless experience without the need for app downloads or sign-ins. Health Note optimizes clinic workflows and encourages patient engagement in their own care.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals affected by skin diseases. Founded in 2019 and based in Chapel Hill, North Carolina, the company aims to enhance the health and well-being of pets by creating treatments for conditions such as atopic dermatitis and osteoarthritis. Aniluxx Biotechnology’s approach leverages a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects often associated with systemic medicines. Through its commitment to improving animal care, Aniluxx Biotechnology seeks to provide pet owners with effective solutions for managing their pets' health issues.

Onena Medicines is a biotechnology company focused on developing innovative biological therapies to meet significant clinical needs, particularly in breast cancer and other serious orphan diseases. The company utilizes a proprietary antibody drug discovery platform that leverages advanced artificial intelligence to reprogram cancer cells for the treatment of advanced cancers. This platform enables the design of custom antibodies that exhibit high selectivity and specificity, linked to specialized cellular reprogramming assays. The therapeutic candidates developed by Onena Medicines modulate the activity of a novel class of growth factors known as dual smad inhibiting protein dips, which are implicated in the growth and metastasis of cancer. Through its pioneering approach, Onena Medicines aims to provide physicians with access to groundbreaking drugs in areas where medical needs remain unaddressed.

InvivoSciences is a biotechnology company focused on enhancing drug discovery and repositioning through innovative phenotypic compound screening services. By leveraging advanced tissue engineering techniques combined with assay automation and sample miniaturization, the company provides a cost-effective and rapid platform for therapeutic discovery. InvivoSciences specializes in developing engineered tissue-based assays that closely replicate the biological functions of living organisms, particularly humans and animals. Additionally, the company employs precision medicine approaches by utilizing patient-derived and gene-edited human samples, along with advanced technologies in cell and tissue handling automation, tissue phenotyping assays, and computational biology. This integrated approach enables clinicians to quickly assess the safety and efficacy of treatments tailored to specific patient populations, improving the drug development process before entering costly clinical trials.

Eupnoos is a health-tech company focused on enhancing lung health and disease detection through innovative smartphone technology. Its platform provides clinical-grade, device-agnostic automated lung function testing and data interpretation, accessible via an API for various monitoring devices. Utilizing the smartphone's microphone and camera, Eupnoos enables users to screen, measure, and assess their lung function and symptoms effectively. The company's services support both clinical and consumer-grade applications, facilitating telehealth and remote patient monitoring. By offering tools that help individuals understand their lung health, Eupnoos empowers users to access wellness monitoring and improve clinical decision-making with professional guidance.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Savvy Cooperative is a company that operates a platform focused on sharing health experiences within the healthcare industry. The platform enables patients to directly share their health journeys with innovators in the field, advocating for fair compensation for their contributions. By doing so, Savvy empowers patients to co-create new healthcare solutions, providing them with a sense of purpose and an opportunity to earn money. This approach helps healthcare industries gain valuable patient insights for clinical research, user experience design, and market analysis through various methods such as surveys, interviews, and focus groups.

Limbix is a prescription digital therapeutic company focused on developing innovative mental health treatments specifically for adolescents. The company offers a digital therapeutics platform designed to address the mental health challenges faced by young people, including depression and anxiety. Limbix's first product, SparkRx, enables licensed healthcare professionals to prescribe evidence-based, therapeutic interventions to improve the mental well-being of their patients. The diverse team at Limbix, consisting of clinicians, product designers, researchers, and engineers, combines clinical expertise with technological innovation to create effective digital solutions for adolescent mental health.

Byteflies is a Belgian-American wearable health company dedicated to transforming healthcare through innovative technology. With its headquarters in Antwerp, Belgium, near key life sciences and clinical research centers, and a secondary office in the San Francisco Bay Area, the company is positioned at the intersection of healthcare and digital innovation. Byteflies develops advanced wearable health applications, including a sensor dot that captures biopotential signals, muscle activity, eye movement, and other activity-related data using an integrated inertial measurement unit. This technology empowers pharmaceutical companies, researchers, and tech firms to enhance healthcare delivery and improve patient outcomes. The team comprises experts in medicine, engineering, and data science, all committed to advancing health monitoring and management.

Health Note is an AI chatbot platform based in San Francisco, California, founded in 2018. The company specializes in health data management, focusing on enhancing patient encounters by streamlining the collection of patient information. By sending an SMS link to patients, Health Note connects them to its AI-driven chatbot, which gathers pre-visit data and formats it into physician notes. This process simplifies documentation for healthcare providers and integrates seamlessly with existing electronic medical record systems, ensuring a frictionless experience without the need for app downloads or sign-ins. Health Note optimizes clinic workflows and encourages patient engagement in their own care.

Embleema is a health data platform focused on improving the drug discovery process and accelerating the development of new treatments. The company empowers patients to take ownership of their medical data, facilitating direct connections with research studies and allowing patients to be compensated for sharing their information. By enhancing the collection and sharing of real-world evidence, Embleema aims to transform the traditional linear model of drug approval into a more efficient iterative process. This approach enables the healthcare system to generate regulatory-grade evidence, including genomic sequences and data on microbial pathogens, thereby reducing the time and costs associated with bringing life-saving drugs to market, particularly for patients with rare diseases.

Intus Care, Inc. is a healthcare analytics company that specializes in connecting home care providers with patients through its innovative platform. Founded in 2018 and based in North Providence, Rhode Island, the company leverages machine learning and electronic health records to enhance the efficiency of care delivery. Its application enables provider organizations to conduct electronic visit verification and predict hospital readmissions and utilization risks. Additionally, Intus Care's platform facilitates automatic patient risk grouping and tracking, identifies patients at high risk for hospitalization, and sends alerts regarding changes in patient health status to care coordination teams. By synthesizing financial, clinical, and administrative data, Intus Care helps healthcare organizations, including PACE programs and long-term care facilities, visualize trends and implement data-driven interventions aimed at improving patient care and reducing hospitalizations for vulnerable populations.

CellSpring is a biotechnology company based in Zurich, Switzerland, specializing in the development of 3D micro tissues for diverse biological applications. Its primary technology, the 3D Bloom platform, allows for the rapid creation of biomimetic microtissues that are not dependent on specific cell types. This innovative platform enhances existing 3D cell culture methods by offering improved speed, reliability, versatility, and user-friendliness. By facilitating the production of these advanced microtissues, CellSpring aims to support in vitro studies and contribute to advancements in clinical diagnostics, including the early detection of cancer.

Encapsulate is a biotechnology company focused on developing automated tumor-on-a-chip systems that facilitate personalized cancer treatment. The company's innovative technology allows for the growth of patients' cancer cells outside the body, creating micro tumors that can be preserved and utilized to assess the efficacy of various chemotherapy and biotherapeutic drugs. By screening the response profile of cancer patients to these treatments, Encapsulate aims to enable oncologists to tailor effective treatment regimens, improving outcomes in cancer care.

Intus Care, Inc. is a healthcare analytics company that specializes in connecting home care providers with patients through its innovative platform. Founded in 2018 and based in North Providence, Rhode Island, the company leverages machine learning and electronic health records to enhance the efficiency of care delivery. Its application enables provider organizations to conduct electronic visit verification and predict hospital readmissions and utilization risks. Additionally, Intus Care's platform facilitates automatic patient risk grouping and tracking, identifies patients at high risk for hospitalization, and sends alerts regarding changes in patient health status to care coordination teams. By synthesizing financial, clinical, and administrative data, Intus Care helps healthcare organizations, including PACE programs and long-term care facilities, visualize trends and implement data-driven interventions aimed at improving patient care and reducing hospitalizations for vulnerable populations.

Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.

Combioxin SA is a clinical-stage biotechnology company focused on developing innovative anti-virulence drugs aimed at treating severe bacterial infections and addressing antibiotic resistance. The company's distinctive therapeutic strategy involves the use of engineered liposomes that neutralize virulence effectors, which are harmful components produced by bacteria. This approach is designed to restore health in critically ill patients suffering from severe bacterial pneumonia. By targeting the mechanisms of virulence rather than the bacteria itself, Combioxin seeks to provide effective treatment options in an era where traditional antibiotics are becoming increasingly ineffective.

ATLASense Biomed, founded in 2015 and headquartered in Israel, specializes in advanced medical monitoring solutions that enable remote patient management. The company has developed the PolyMonitor, a chest-worn device designed to provide real-time, multipurpose health surveillance comparable to ICU standards for patients at home. This innovative technology addresses critical issues in respiratory health by predicting deterioration in conditions such as COVID-19, COPD, and ARDS, allowing for early intervention and potentially preventing the need for invasive treatments like intubation. ATLASense's solutions aim to significantly reduce healthcare costs—estimated at over $300 per day per patient—while enhancing patient care and quality of life. The company also offers the REPHAEL platform, which utilizes AI for real-time monitoring of various health conditions, including heart failure and early signs of sepsis. With a target market of one billion individuals, ATLASense strives to deliver effective preventive care through its subscription-based service, ultimately improving clinical outcomes and financial efficiency within healthcare systems.

Combinostics Oy, established in 2014 and based in Tampere, Finland, specializes in developing and marketing advanced software tools for data-driven diagnostics in neurodegenerative diseases. The company's core offering is a cloud-based platform that provides clinical decision support, enabling healthcare professionals to analyze brain images (MR, PET, CT) and make early, informed diagnoses, ultimately enhancing treatment outcomes.

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

Oxalo Therapeutics is a biopharmaceutical company focused on developing innovative drug therapies for rare kidney diseases and the prevention of recurrent kidney stones. The company's primary target is primary hyperoxaluria and other oxalate-related conditions. Leveraging expertise in the microbiome and translational research, Oxalo Therapeutics has developed a novel approach that mimics natural mechanisms for safely removing oxalate from the body. This method aims to effectively prevent the formation of kidney stones and address renal diseases associated with elevated oxalate levels, thereby improving patient outcomes and quality of life.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Stithi Innovation is a healthcare company that focuses on enhancing medication compliance for patients on long-term medication regimens. It has developed a medical device that dispenses pills and monitors daily dosages over extended periods. By integrating real-time monitoring services and built-in cellular connections, Stithi's devices facilitate remote tracking of medication adherence by both healthcare providers and patients. This innovative approach aims to improve patient outcomes by ensuring that individuals adhere to their prescribed treatment plans.

Hippocrate is a healthcare organization founded in 2014 and based in Tunis, Tunisia, that operates a cloud-based big data medical platform focused on analyzing the human genome. The company provides a healthcare analytics platform that facilitates the sharing of patient medical data among various hospitals, allowing authorized medical professionals to access this information during doctor visits or emergencies. By enabling the connection and organization of medical data, Hippocrate enhances the accessibility and utility of patient information for healthcare providers and contributes to medical research. The platform aims to improve healthcare access for patients worldwide, particularly those in underserved communities.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

ImmunArtes is a biotechnology company focused on developing vaccines and therapeutics to combat staphylococcus aureus, including its antibiotic-resistant strains. The company aims to address the immune evasion mechanisms employed by these bacteria, which contribute to increased rates of antibiotic resistance and challenges in treatment. ImmunArtes is dedicated to providing effective vaccination solutions that protect patients from staph infections, with a strong emphasis on demonstrating efficacy in preclinical models. Through its innovative approach, the company seeks to enhance patient outcomes by preventing colonization and the diseases associated with these pathogens.

Pilleve is a company focused on addressing the critical issue of opioid misuse and addiction, which has significantly impacted many Americans. By providing a remote monitoring system, Pilleve aims to reduce the risks associated with opioid prescriptions through real-time data collection and behavioral analysis. Their solution features an integrated pill bottle and a corresponding smartphone application that securely dispenses medication while monitoring patient intake. Patients must use biometric scanners or passwords to access their prescriptions, and they are prompted to report their pain levels and mood before dispensing medication. This process allows for the early detection of problematic behaviors, enabling healthcare providers to intervene promptly if patients exceed recommended dosages. By facilitating communication between patients and their physicians through electronic health records, Pilleve strives to improve patient safety and care, ultimately reducing the social and financial burdens tied to opioid addiction for patients and their families.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. The company specializes in a platform that utilizes data from small molecules, or metabolites, applying a network-based machine learning algorithm to conduct integrative analyses of untargeted metabolomic data alongside other extensive molecular information, such as data from genes, proteins, drugs, and diseases. This innovative approach transforms metabolomic data into actionable insights, facilitating the development of in-house therapeutics tailored for patients suffering from liver diseases and related conditions. ReviveMed aims to enhance health outcomes by unlocking the potential of metabolomics in medical research and treatment.

Halo Life Science is a company dedicated to enhancing human health and wellness through innovative nutritional solutions. After three years of research and development, the company has introduced Naturalin™, a patent-pending phytonutrient designed to improve the nutritional value of everyday foods and beverages. This multifunctional bioactive is also available in various nutritional supplement formats, making it suitable for addressing chronic conditions, illnesses, and obesity. Supported by research from the Dell Pediatric Research Institute at The University of Texas at Austin, Naturalin™ has been validated for safety and efficacy. Halo Life Science's mission is to provide safe, effective, and accessible food and nutritional products to consumers, ensuring that enhanced nutrition is available to everyone, everywhere.

Healthimation is a healthcare company focused on addressing weight management issues, specifically for individuals with Type 2 Diabetes, Pre-Diabetes, and Obesity. Its flagship program, Why WAIT™, has over 12 years of proven effectiveness and combines structured meal plans, exercise regimens, and educational resources with engaging entertainment elements. This innovative approach ensures that users remain motivated and committed to their personalized health journeys. Healthimation's platform integrates evidence-based clinical programs with digital health technology, utilizing animation and interactive learning to enhance user engagement and improve health outcomes. By providing an affordable and scalable solution, Healthimation stands out in the market for its unique ability to deliver clinical care in a captivating manner that resonates with users and fosters better health management.

ThinkGenetic is an innovative online platform focused on assisting patients in understanding the genetic factors related to their medical conditions. By leveraging cognitive technology, the platform provides users with insights into potential genetic causes of their health issues and offers guidance on relevant questions to pose to healthcare professionals. This approach aims to accelerate the diagnostic process and minimize the risk of diagnostic errors, ultimately enhancing the quality of medical care for individuals affected by genetic diseases. ThinkGenetic's mission is to empower patients with knowledge, thereby improving their healthcare experiences and outcomes.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

MobioSense is engaged in the development of advanced diagnostic solutions for heart disease. The company's flagship product, HERO, is a portable, high-sensitivity troponin test that enables rapid diagnosis of heart attacks. Unlike conventional tests that require multiple samples over an extended period, HERO can provide results in just three hours, facilitating immediate decision-making in both hospital and ambulance settings. This innovation not only improves patient care by allowing for timely interventions but also helps alleviate emergency room congestion by directing patients to the appropriate care pathways. In addition to its heart disease monitoring capabilities, MobioSense is also involved in creating detection reagents for diseases such as African Swine Fever and COVID-19, further enhancing its commitment to healthcare advancements.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

MakerHealth is a health network focused on democratizing the tools and processes for health technology innovation. Originating from the MIT Little Devices Lab in 2008, the company has evolved from its academic roots to actively engage with frontline medical staff, empowering them to transition from healthcare providers to innovators. Through initiatives like the MakerNurse project, MakerHealth fosters a community of health makers who design and fabricate their own medical devices, enhancing patient care in diverse settings. The organization provides resources, tools, and educational opportunities that enable individuals to experiment and develop new skills in health technology fabrication. By creating environments such as MakerHealth Spaces and offering prototyping kits, the company supports the development of healthcare products that are both accessible and effective, ultimately striving to make health technology more affordable and user-driven. MakerHealth believes in the potential of everyone to contribute to medical innovation, ensuring that the tools for healing are within reach of those who need them most.

NerveSolutions is a biomedical technology company focused on creating advanced implantable nerve interface devices. The company has developed a surgical device that aims to prevent the formation of neuromas following amputation or nerve injury. This bioengineered device is designed to be placed on the cut ends of nerves, effectively inhibiting the development of painful neuromas. By doing so, NerveSolutions enables surgeons to deliver optimal care to patients with peripheral nerve injuries, helping them regain functionality through innovative treatment options.

Every day more than 1 million implants are placed into human and animal bodies using open surgery. Lumigbo has developed a technology to build up implants inside the body using an access channel of less than half a millimeter in diameter. The procedure can be used for almost any type of implant. We have developed minimally viable prototypes for neurovascular, orthopedic and dental applications. Currently, we are improving our prototypes and expect to close round A in the third quarter of 2018.

Structured Immunity is a protein engineering company focused on enhancing the safety and effectiveness of T cell receptor-based therapies. Founded in 2017 by David Hardwicke and Timothy Riley, the company leverages over 20 years of research from the laboratory of Brian Baker to develop advanced techniques for optimizing T cell receptors. By increasing the target specificity of these receptors, Structured Immunity aims to improve drug efficacy while minimizing potential side effects associated with T cell therapies. The company specializes in enhancing the human immune system for cell-based cancer immunotherapy, providing pharmaceutical firms with innovative solutions for engineering patentable cellular cancer therapies with improved tumor targeting capabilities.

SuraMedical LLC, founded in 2016, is an early-stage startup dedicated to the research, development, and commercialization of WoundAlert, a remote patient monitoring solution aimed at improving care for chronic leg wounds. These wounds affect millions of Americans annually, leading to significant healthcare challenges. SuraMedical's device promotes patient compliance with essential practices like walking and leg elevation while also monitoring key factors such as the saturation of primary wound dressings and pressure from compression bandages. This capability facilitates intelligent scheduling of dressing changes, ultimately helping patients manage their conditions more effectively. The company benefits from a robust network of consultants specializing in wound care reimbursement, FDA regulations, clinical research, patent law, and healthcare compliance, enhancing its ability to navigate the complexities of the healthcare landscape.

Jane Diagnostics has developed an innovative healthcare technology aimed at improving the detection of human papillomavirus (HPV) and, consequently, cervical cancer. The company offers a low-cost, easy-to-use diagnostic test that allows minimally trained health workers to conduct screenings in remote areas, providing results in under one hour. This technology integrates sample processing and DNA amplification, making it possible to detect various HPV genotypes without the need for extensive laboratory infrastructure or long transportation times. By simplifying the testing process, Jane Diagnostics is positioned to revolutionize HPV screening, particularly in developing regions, thereby enhancing early detection and potentially reducing cervical cancer incidence.

General Biotechnologies identifies and develops undervalued discoveries in the life sciences. Their flagship program — Nivien Therapeutics — is a venture-backed oncology startup spun out of Harvard Medical School.